Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: A double-blind, randomised, multicentre, historical control study

Epilepsy Research

Volumn 101, Issue 1-2, 2012, Pages 92-102

  Chung, Steve ^a   Ceja, Hugo ^b   Gawłowicz, Jacek ^c   Avakyan, Gagik ^d   McShea, Cindy ^e   Schiemann, Jimmy ^e   Lu, Sarah ^e  

^a ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^b HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^c State Hospital   (Poland)

^d PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^e UCB PHARMA   (Belgium)

Author keywords

Antiepileptic drug; Epilepsy; Historical control; Levetiracetam; Monotherapy; Partial onset seizures

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; PLACEBO; TOPIRAMATE; VALPROIC ACID;

ABDOMINAL PAIN; ABNORMAL THINKING; ACUTE PSYCHOSIS; AGED; ARTICLE; CHILD; CONFUSION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CONVULSION; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTENDED RELEASE FORMULATION; FEMALE; FOCAL EPILEPSY; FOLLOW UP; HEADACHE; HEMORRHOID HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PARTIAL ONSET SEIZURE; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; VERTIGO;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CHILD; DOUBLE-BLIND METHOD; EPILEPSIES, PARTIAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PIRACETAM; SAMPLE SIZE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865075460     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2012.03.007     Document Type: Article

References (31)

1. Baulac M. Rational conversion from antiepileptic polytherapy to monotherapy. Epileptic Disord. 2003, 5:125-132.
2. Ben-Menachem E., Falter U. Efficacy and tolerability of levetiracetam 3000mg/day in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000, 41:1276-1283.
3. Berkovic S.F., Knowlton R.C., Leroy R.F., Schiemann J., Falter U. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy; Levetiracetam N01057 Study Group. Neurology 2007, 69:1751-1760.
4. Brodie M.J., Perucca E., Ryvlin P., Ben-Menachem E., Meencke H.J. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007, 68:402-408.
5. Carpay J.A., Aldenkamp A.P., van Donselaar C.A. Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure 2005, 14:198-206.
6. Cereghino J.J., Biton V., Abou-Khalil B., et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000, 55:236-242.
7. Faught E. Monotherapy in adults and elderly persons. Neurology 2007, 69:S3-S9.
8. French, J.A., Wang, S., Warnock, B., Temkin, N. Alternative monotherapy design in the treatment of epilepsy [White paper], 2009.
9. French J.A., Wang S., Warnock B., Temkin N. Historical control monotherapy design in the treatment of epilepsy. Epilepsia 2010, 51:1936-1943.
10. Gilliam F., Vazquez B., Sackellares J.C., et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998, 51:1018-1025.
11. Glauser T.A., Ayala R., Elterman R.D., et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006, 66:1654-1660.
12. Harms S.L., Eberly L.E., Garrard J.M., et al. Prevalence of appropriate and problematic antiepileptic combination therapy in older people in the nursing home. J. Am. Geriatr. Soc. 2005, 53:1023-1028.
13. International League Against, Epilepsy Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1981, 22:489-501.
14. Katz R. Issues in clinical trial design from the FDA perspective. Epilepsia 2003, 44(Suppl. 7):9-15.
15. Katz R. FDA update. Epilepsy Res. 2006, 68:85-94.
16. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 2000, 342:314-319.
17. Marson A.G., Williamson P.R. Interpreting regulatory trials in epilepsy. Curr. Opin. Neurol. 2009, 22:167-173.
18. Mattson R.H., Cramer J.A., Collins J.F., et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N. Engl. J. Med. 1985, 313:145-151.
19. Noachtar S., Andermann E., Meyvisch P., et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008, 70:607-616.
20. Patsalos P.N., Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003, 2:347-356.
21. Peltola J., Coetzee C., Jimenez F., et al. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Epilepsia 2009, 50:406-414.
22. Perucca E. Extended-release formulations of antiepileptic drugs: rationale and comparative value. Epilepsy Curr. 2009, 9:153-157.
23. Perucca E., Tomson T. Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Epilepsy Res. 1999, 33:247-262.
24. Piña-Garza J.E., Schiemann Delgado J., Yang H. Adjunctive levetiracetam in patients aged 1 month to <4 years with partial-onset seizures: sub-population analysis of a prospective, open-label extension study up to 48 weeks. Clin. Ther. 2010, 32:1935-1950.
25. Pohlmann-Eden B., Van Paesschen W., Hallstrom Y., et al. The KOMET study: an open-label, randomized, parallel-group trial comparing the efficacy and safety of levetiracetam with sodium valproate and carbamazepine as monotherapy in subjects with newly diagnosed epilepsy. 62nd Annual Meeting of the American Epilepsy Society 2008.
26. Richy F.F., Banerjee S., Brabant Y., Helmers S. Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques. Epilepsy Behav. 2009, 16:240-245.
27. Rouits E., Burton I., Guenole E., et al. Pharmacokinetics of levetiracetam XR 500mg tablets. Epilepsy Res. 2009, 84:224-231.
28. Sachdeo R., Beydoun A., Schachter S., et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology 2001, 57:864-871.
29. Schiemann-Delgado J., Yang H., De La Loge C., et al. A long-term open-label extension study assessing cognition and behavior, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4-16 years with partial-onset seizures. J. Child Neurol. 2012, 27:80-89.
30. Shorvon S.D., Lowenthal A., Janz D., Bielen E., Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000, 41:1179-1186.
31. St Louis E.K., Rosenfeld W.E., Bramley T. Antiepileptic drug monotherapy: the initial approach in epilepsy management. Curr. Neuropharmacol. 2009, 7:77-82.